Literature DB >> 8180255

Summary of clinical experience with recombinant factor VIII products--Kogenate.

J M Lusher1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8180255     DOI： 10.1007/bf01774521

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

Authors:  R S Schwartz; C F Abildgaard; L M Aledort; S Arkin; A L Bloom; H H Brackmann; D B Brettler; H Fukui; M W Hilgartner; M J Inwood
Journal:  N Engl J Med       Date:  1990-12-27       Impact factor: 91.245

2.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

Authors:  J Addiego; C Kasper; C Abildgaard; M Hilgartner; J Lusher; B Glader; L Aledort
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

3.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

Authors:  S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

4.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Authors:  J M Lusher; S Arkin; C F Abildgaard; R S Schwartz
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.